Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Llewellyn Mills

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Drug and Alcohol Review|February 16, 2022
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical conditionLlewellyn Mills, Nicholas Lintzeris, Michael O'Malley, et al.
BMC Public Health|February 2, 2024
The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational studyBenjamin T Trevitt, Victoria Hayes, Rachel Deacon, et al.
Nature and Science of Sleep|April 24, 2023
Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 SurveyAnastasia Suraev, Llewellyn Mills, Sarah V Abelev, et al.
Accident; Analysis and Prevention|October 5, 2020
Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 SurveyThomas R Arkell, Nicholas Lintzeris, Llewellyn Mills, et al.
Harm Reduction Journal|July 30, 2022
Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)Nicholas Lintzeris, Llewellyn Mills, Sarah V Abelev, et al.
Substance Abuse Treatment, Prevention, and Policy|October 8, 2022
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorderLlewellyn Mills, Adrian Dunlop, Mark Montebello, et al.
Drug and Alcohol Review|May 13, 2020
Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populationsRachel M Deacon, Kristie Mammen, Jennifer Holmes, et al.
Plos One|February 14, 2024
Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide studyBenjamin T Trevitt, Sasha Bailey, Llewellyn Mills, et al.
Journal of Cannabis Research|September 6, 2023
Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 surveyThomas R Arkell, Sarah V Abelev, Llewellyn Mills, et al.
Drug and Alcohol Dependence|June 24, 2026
The impact of severe mental illness on treatment retention and all-cause mortality among people in opioid agonist treatmentNatasa Gisev, Thomas Santo, Julia Lappin, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Drug and Alcohol Review|February 16, 2022
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical conditionLlewellyn Mills, Nicholas Lintzeris, Michael O'Malley, et al.
BMC Public Health|February 2, 2024
The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational studyBenjamin T Trevitt, Victoria Hayes, Rachel Deacon, et al.
Nature and Science of Sleep|April 24, 2023
Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 SurveyAnastasia Suraev, Llewellyn Mills, Sarah V Abelev, et al.
Accident; Analysis and Prevention|October 5, 2020
Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 SurveyThomas R Arkell, Nicholas Lintzeris, Llewellyn Mills, et al.
Harm Reduction Journal|July 30, 2022
Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)Nicholas Lintzeris, Llewellyn Mills, Sarah V Abelev, et al.
Substance Abuse Treatment, Prevention, and Policy|October 8, 2022
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorderLlewellyn Mills, Adrian Dunlop, Mark Montebello, et al.
Drug and Alcohol Review|May 13, 2020
Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populationsRachel M Deacon, Kristie Mammen, Jennifer Holmes, et al.
Plos One|February 14, 2024
Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide studyBenjamin T Trevitt, Sasha Bailey, Llewellyn Mills, et al.
Journal of Cannabis Research|September 6, 2023
Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 surveyThomas R Arkell, Sarah V Abelev, Llewellyn Mills, et al.
Drug and Alcohol Dependence|June 24, 2026
The impact of severe mental illness on treatment retention and all-cause mortality among people in opioid agonist treatmentNatasa Gisev, Thomas Santo, Julia Lappin, et al.
Pageof 5